BALI Concept

The BALI consortium performs multidisciplinary research to design Synthetic Antimicrobial Antibiofilm Peptides (SAAP) and a release system which can be applied to the surface of biomaterials as a coating. We aim to develop novel SAAPs with optimized in vitro antimicrobial, anti-inflammatory and biofilm-dispersing activity (WP2) and to investigate their mode of action (WP3). An innovative delivery formulation (PolyPid platform) will be used to allow prolonged and pre-determined release rates of the most promising SAAPs (WP4). This platform ensures local delivery of effective concentrations of the peptide over a sufficient duration and can be developed into coatings for different types of implants. To obtain in vivo proof of concept, the efficacy to prevent and treat biomaterial-associated infections of PolyPid/SAAP-coated polymer and titanium implants will be tested in various clinically relevant in vivo model systems (WP5 and WP6). Results will be actively disseminated to specialized and general audiences (WP8).

In 2016 a new workpackage was added to the program, in which the most promising peptide from the program will be further characterised for clinical research that will happen afthe the BALI program. The participating company Madam Therapeutics will be responsible for the conduct of this study